NOSE TO BRAIN DELIVERY OF FROVATRIPTAN LOADED IN PLGA NANOPARTICLES: A PROMISING APPROACH FOR MIGRAINE THERAPY
DOI:
https://doi.org/10.22159/ajpcr.2025v18i10.55432Keywords:
Frovatriptan succinate, Migraine, Nanoparticles,, 32 factorial designs, poly (lactic-co-glycolic acid),, NanoprecipitationAbstract
Objectives: The objective of the research was to formulate and evaluate frovatriptan succinate (FS)-loaded poly (lactic-co-glycolic acid) (PLGA) nanoparticles (NP) for migraine therapy to improve its therapeutic effect and reduce dosing frequency.
Methods: The objective of the present study was to develop FS-loaded NP for brain targeting to improve bioavailability, decrease dose and frequency of dosing, reduce side effects, and improve therapeutic efficacy. A 32 factorial design was employed to formulate a nanoparticulate drug delivery system using PLGA. PLGA NP were prepared by the nanoprecipitation technique and characterized for particle size, zeta potential, surface morphology, entrapment efficiency (EE), and in vitro drug release.
Results: The particle size of the optimized formulation NPopt was found to be 236.1 nm±0.21 nm with EE 63.82±0.643%. Zeta potential was found to be −30.3 mV. Transmission electron microscopy studies indicated that the NPs were spherical with smooth surface. NPopt gave 84.15±1.308% sustained release in phosphate buffered saline pH 6.4 after 24 h, following Quasi-Fickian diffusion-based release mechanism. Stability study showed that the formulation NPopt was more stable at 5±1°C than room temperature. These results showed that FS-loaded PLGA NP can be a potential carrier for brain targeting.
Conclusion: The results suggest that FS-loaded PLGA NP can be a potential carrier for brain targeting with promising therapeutic action.
Downloads
References
1. Rigaut C, Deruyver L, Goole J, Lambert P, Haut B. A comprehensive analytical model for predicting drug absorption in the olfactory region: Application to nose-to-brain delivery. Int J Pharm. 2025;674:125392. doi: 10.1016/j.ijpharm.2025.125392, PMID 40032234
2. Razavi ZS, Razavi FS, Alizadeh SS. Inorganic nanoparticles and blood-brain barrier modulation: Advancing targeted neurological therapies. Eur J Med Chem. 2025;287:117357. doi: 10.1016/j. ejmech.2025.117357, PMID 39947054
3. Liu J, Wang T, Dong J, Lu Y. The blood-brain barriers: Novel nanocarriers for central nervous system diseases. J Nanobiotechnology. 2025;23(1):146. doi: 10.1186/s12951-025-03247-8, PMID 40011926
4. Cayero-Otero MD, Perez-Caballero L, Suarez-Pereira I, Hidalgo- Figueroa M, Delgado-Sequera A, Montesinos JM, et al. Venlafaxine-plga nanoparticles provide a fast onset of action in an animal model of depression via nose-to-brain. Int J Pharm. 2025;678:125692. doi: 10.1016/j.ijpharm.2025.125692, PMID 40339630
5. Razavi ZS, Alizadeh SS, Razavi FS, Souri M, Soltani M. Advancing neurological disorders therapies: Organic nanoparticles as a key to blood-brain barrier penetration. Int J Pharm. 2025;670:125186. doi: 10.1016/j.ijpharm.2025.125186, PMID 39788400
6. Gänger S, Schindowski K. Tailoring formulations for intranasal nose-to-brain delivery: A review on architecture, physico-chemical characteristics and mucociliary clearance of the nasal olfactory mucosa. Pharmaceutics. 2018;10(3):116. doi: 10.3390/pharmaceutics10030116, PMID 30081536
7. Gieszinger P, Kiss T, Szabó-Révész P, Ambrus R. The development of an in vitro horizontal diffusion cell to monitor nasal powder penetration inline. Pharmaceutics. 2021;13(6):809. doi: 10.3390/ pharmaceutics13060809, PMID 34071664
8. Alghareeb S, Asare-Addo K, Conway BR, Adebisi AO. PLGA nanoparticles for nasal drug delivery. J Drug Deliv Sci Technol. 2024;95:105564. doi: 10.1016/j.jddst.2024.105564
9. Kataria I, Shende P. Nose-to-brain lipid nanocarriers: An active transportation across BBB in migraine management. Chem Phys Lipids. 2022;243:105177. doi: 10.1016/j.chemphyslip.2022.105177, PMID 35122739
10. Bhyan B, Bhatt DC, Jangra S. Pharmacokinetic study in humans and in vitro evaluation of bioenhanced bilayer sublingual films ForThe management of acute migraine. Int J Appl Pharm. 2023;15(3):190-9. doi: 10.22159/ijap.2023v15i3.46684
11. Villalón CM, Centurión D, Valdivia LF, De Vries P, Saxena PR. Migraine: Pathophysiology, pharmacology, treatment and future trends. Curr Vasc Pharmacol. 2003;1(1):71-84. doi: 10.2174/1570161033386826, PMID 15320857
12. Singh H, Singla YP, Narang RS, Pandita D, Singh S, Narang JK. Frovatriptan loaded hydroxy propyl methyl cellulose/treated chitosan based composite fast dissolving sublingual films for management of migraine. J Drug Deliv Sci Technol. 2018;47:230-9. doi: 10.1016/j. jddst.2018.06.018
13. Kelman L. Review of frovatriptan in the treatment of migraine. Neuropsychiatr Dis Treat. 2008;4(1):s1871. doi: 10.2147/ndt.s1871, PMID 18728819
14. Negro A, Lionetto L, Casolla B, Lala N, Simmaco M, Martelletti P. Pharmacokinetic evaluation of frovatriptan. Expert Opin Drug Metab Toxicol. 2011;7(11):1449-58. doi: 10.1517/17425255.2011.622265, PMID 21929465
15. Sawant SH, Mujawar A. Antimigraine activity of methanolic extract of Abroma augusta L. In laboratory animals. Int J Pharm Pharm Sci. 2022;14:54-9. doi: 10.22159/Ijpps.2022v14i11.45810
16. Saleh A, Khalifa M, Shawky S, Bani-Ali A, Eassa H. Zolmitriptan intranasal spanlastics for enhanced migraine treatment; Formulation parameters optimized via quality by design approach, Sci Pharm. 2021;89:24. doi: 10.3390/scipharm89020024
17. Akel H, Ismail R, Katona G, Sabir F, Ambrus R, Csóka I. A comparison study of lipid and polymeric nanoparticles in the nasal delivery of meloxicam: Formulation, characterization, and in vitro evaluation. Int J Pharm. 2021;604:120724. doi: 10.1016/j.ijpharm.2021.120724, PMID 34023443
18. Kurniawan DW, Aini Gumilas NS, Arramel N, Hartati N, Novrial D, Tarwadi N. Preparation, characterization, and toxicity study of Andrographis paniculata ethanol extract poly-lactic-Co-glycolic acid (Plga) nanoparticles in raw 264.7 cells. Int J Appl Pharm. 2024;16:78-83. doi: 10.22159/ijap.2024v16i4.50798
19. Albash R, Fahmy AM, Shamsel-Din HA, Ibrahim AB, Bogari HA, Malatani RT, et al. Intranasal propranolol hydrochloride-loaded PLGA-lipid hybrid nanoparticles for brain targeting: Optimization and biodistribution study by radiobiological evaluation. Eur J Pharm Sci. 2025;208:107061. doi: 10.1016/j.ejps.2025.107061, PMID 40057137
20. Sreeharsha N, Prasanthi S, Rao GS, Gajula LR, Biradar N, Goudanavar P, et al. Formulation optimization of chitosan surface coated solid lipid nanoparticles of griseofulvin: A Box-Behnken design and in vivo pharmacokinetic study. Eur J Pharm Sci. 2025;204:106951. doi: 10.1016/j.ejps.2024.106951, PMID 39486655
21. Tezel G, Ulutürk S, Reçber T, Timur SS, Nemutlu E, Esendağlı G, et al. Preparation and in vitro characterization of memantine HCl loaded PLGA nanoparticles for Alzheimer’s disease. J Drug Deliv Sci Technol. 2024;100:106142. doi: 10.1016/j.jddst.2024.106142
22. Phalak SD, Bodke V, Yadav R, Pandav S, Ranaware M. A systematic review on Nano drug delivery system: Solid lipid nanoparticles (SLN). Int J Curr Pharm Res. 2024;16:10-20. doi: 10.22159/ ijcpr.2024v16i1.4020
23. Shah P, Sarolia J, Vyas B, Wagh P, Ankur K, Kumar MA. PLGA nanoparticles for nose to brain delivery of clonazepam: Formulation, optimization by 32 factorial design, in vitro and in vivo evaluation. Curr Drug Deliv. 2021;18(6):805-24. doi: 10.2174/15672018176662007081 15627, PMID 32640955
24. Tong GF, Qin N, Sun LW. Development and evaluation of desvenlafaxine loaded PLGA-chitosan nanoparticles for brain delivery. Saudi Pharm J. 2017;25(6):844-51. doi: 10.1016/j.jsps.2016.12.003, PMID 28951668
25. Piazzini V, Landucci E, D’Ambrosio M, Fasiolo LT, Cinci L, Colombo G, et al. Chitosan coated human serum albumin nanoparticles: A promising strategy for nose-to-brain drug delivery. Int J Biol Macromol. 2019;129:267-80. doi: 10.1016/j.ijbiomac.2019.02.005, PMID 30726749
26. Öztürk K, Kaplan M, Çalış S. Effects of nanoparticle size, shape, and zeta potential on drug delivery. Int J Pharm. 2024;666:124799. doi: 10.1016/j.ijpharm.2024.124799, PMID 39369767
27. Wilson BK, Prud’homme RK. Nanoparticle size distribution quantification from transmission electron microscopy (TEM) of ruthenium tetroxide-stained polymeric nanoparticles. J Colloid Interface Sci. 2021;604:208-20. doi: 10.1016/j.jcis.2021.04.081
28. Khalbas AH, Albayati TM, Ali NS, Salih IK. Drug loading methods and kinetic release models using of mesoporous silica nanoparticles as a drug delivery system: A review. S Afr J Chem Eng. 2024;50:261-80. doi: 10.1016/j.sajce.2024.08.013
29. Sultana S, Alzahrani N, Alzahrani R, Alshamrani W, Aloufi W, Ali A, et al. Stability issues and approaches to stabilised nanoparticles based drug delivery system. J Drug Target. 2020;28(5):468-86. doi: 10.1080/1061186X.2020.1722137, PMID 31984810
30. Dikpati A, Maio VD, Ates E, Greffard K, Bertrand N. Studying the stability of polymer nanoparticles by size exclusion chromatography of radioactive polymers. J Control Release. 2024;369:394-403. doi: 10.1016/j.jconrel.2024.03.053, PMID 38556217
31. Selvamani V. Stability Studies on Nanomaterials Used in Drugs. Netherlands: Elsevier; 2019. p. 425-44. doi: 10.1016/b978-0-12- 814031-4.00015-5
32. Todaro B, Moscardini A, Luin S. Pioglitazone-loaded plga nanoparticles: Towards the most reliable synthesis method. Int J Mol Sci 2022;23:2522. doi: 10.3390/ijms23052522
33. Kunnumakkara AB, Hegde M, Parama D, Girisa S, Kumar A, Daimary, UD. Role of turmeric and curcumin in prevention and treatment of chronic diseases: Lessons learned from clinical trials. ACS Pharmacol Transl Sci 2023;6:447-518. doi: 10.1021/acsptsci.2c00012
34. Haasbroek-Pheiffer A, Niekerk SV, der Kooy FV, Cloete T, Steenekamp J, Hamman J. In vitro and ex vivo experimental models for evaluation of intranasal systemic drug delivery as well as direct nose-to-brain drug delivery. Biopharm Drug Dispos 2023;44:94-112. doi: 10.1002/ bdd.2348
Published
How to Cite
Issue
Section
Copyright (c) 2025 Mr. Ajeet Kumar
This work is licensed under a Creative Commons Attribution 4.0 International License.
The publication is licensed under CC By and is open access. Copyright is with author and allowed to retain publishing rights without restrictions.
